Full Press Release Details
Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody.
BIIB
Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody
Key Takeaway: Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody
Price reaction · baseline $226 (2022-01-31 close) · hit after-hours · 1 other BIIB headline(s) in the window, move may be shared
day 0 close · peak
+1.5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis